2007 Fiscal Year Final Research Report Summary
A study about the anticancer agent-related gene change in the human lung cancer orthotopic implantation model
| Project/Area Number |
18591552
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Department of Clinical Research, National Hospital Organization Tokushima National Hospital (2007)
The University of Tokushima (2006) |
|---|
Principal Investigator |
MIYOSHI Takanori Department of Clinical Research, National Hospital Organization Tokushima National Hospital, 独立行政法人国立病院機構・徳島病院臨床研究部, Head physician (20346612)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KONDO Kazuya University of Tokushima, Department of Medicine, Professor (10263815)
TOBA Hiroaki NHO Tokushima Hospital, University of Tokushima Hospital, Medical staff (40403745)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Keywords | esophageal cancer / thyroid anaplastic carcinoma / lung cancer / orthotopic implantation model / lymph node metastasis / metastasis related gene / anti cancer agent related gene / TaqMan Low Density Array |
|---|
| Research Abstract |
The human lung cancer orthotopic implantation model uses an SCID mouse and forms the primary tumor and succeeds in making the mediastinal lymph node metastasis model. It is the rare for the cancer model. Therefore, using ACT-1 cells (anaplastic carcinoma of thyroid) and YES-3 cells (esophageal cancer), we made the human cancer cell models with SCID mouse. The method fixes the SCID mouse in face up position under the anesthesia. We shut stomach after adding about 1.5cm horizontal incision to an epigastric region in the case of the gullet and perform an operation and expose the esophagus, and having injected cell suspension 10 μ ml which we prepared beforehand in the esophageal muscular layer with 30G needle. We shut wound after adding horizontal incision to a cervix in the case of the thyroid gland and expose the trachea and confirm the thyroid gland, and having injected cell suspension 10 μ ml in the thyroid gland with 30G needle. Four weeks later, the model formed micro-metastases in
… More
six weeks, and formed macro-metastases in eight weeks. In addition, the thyroid carcinoma did neoplasia in the thyroid gland in injection six weeks and understood that caused mediastinum lymph node metastasis in eight weeks. Because it was able to reproduce lymph node metastasis of the cancer of the human esophageal cancer in the mouse, each thyroid carcinoma, there was it of contribution preparations to the magazine of the cancer connection now because I perform these supplementary examinations, and it was possible for a course in correct time in progress to make the metastasis from neoplasia.
In addition, we performed the anticancer agent dosage, and it was the examination of the anticancer agent in the tumor-related gene change, but we decided to perform it in a model under the skin before aforementioned place transplant model, and making of, 5-FU and CDDP administered a tumor to the SCID mouse subcutaneous about a YES-3 cell between things of resistant acquisition during the dosage. We gathered each tumor organization at the time of effect expression the anticancer agent dosage ago at resistant acquisition time. For genetic norrowing, I searched it in DNA array. It was suggested that PI3K/Akt signaling pathway was related to resistant acquisition. I perform the anticancer agent dosage with the aforementioned place transplant model mentioned above and am going to perform a study about the anticancer agent connection gene change in the orthotopic implantation model. Less
|
Research Products
(2 results)
